Core Insights - Revolution Medicines, Inc. reported its financial results for Q4 and full year 2024, highlighting advancements in its RAS-focused oncology pipeline and a strong financial position [1][3][25]. Company Overview - The company is focused on developing targeted therapies for RAS-addicted cancers, with a pipeline that includes daraxonrasib, elironrasib, and zoldonrasib [2][37]. Clinical Development Highlights - In 2024, the company made significant progress in its clinical trials, particularly for pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC) [3][4]. - Daraxonrasib showed promising results in PDAC, with a median progression-free survival (PFS) of 8.8 months for patients with KRAS G12X mutations [4][5]. - The company is advancing daraxonrasib into pivotal trials for earlier lines of treatment in PDAC and NSCLC, with expected data readouts in 2026 [7][19][18]. Financial Performance - The company raised $823 million in a public equity offering in December 2024, strengthening its financial position [25][26]. - As of December 31, 2024, cash, cash equivalents, and marketable securities totaled $2.3 billion, up from $1.9 billion in 2023 [27]. - Research and development expenses for Q4 2024 were $188.1 million, an increase from $148.5 million in Q4 2023, primarily due to clinical trial costs [28]. - The net loss for Q4 2024 was $194.6 million, compared to a net loss of $161.5 million in Q4 2023 [30]. Strategic Priorities - The company has outlined five strategic priorities for 2025, including executing pivotal trials, advancing its pipeline, and enhancing commercial capabilities [17][19][24]. - Plans include initiating pivotal trials for daraxonrasib in earlier lines of treatment for PDAC and expanding its RAS(ON) inhibitor combinations [19][21][22]. Future Outlook - The company expects a full-year 2025 GAAP net loss between $840 million and $900 million, with sufficient cash to fund operations into the second half of 2027 [35].

Company Overview - Revolution Medicines, Inc. is a late-stage clinical oncology company focused on developing novel targeted therapies for patients with RAS-addicted cancers [2] - The company's R&D pipeline includes RAS(ON) inhibitors designed to suppress various oncogenic variants of RAS proteins [2] Product Pipeline - Key RAS(ON) inhibitors in clinical development include: - Daraxonrasib (RMC-6236), a multi-selective inhibitor - Elironrasib (RMC-6291), a G12C-selective inhibitor - Zoldonrasib (RMC-9805), a G12D-selective inhibitor [2] - Additional development opportunities focus on RAS(ON) mutant-selective inhibitors such as RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C) [2] Investor Engagement - The CEO Mark A. Goldsmith will participate in three upcoming investor conferences: - TD Cowen 45 Annual Healthcare Conference on March 3 at 1:50 p.m. ET - Barclays 27 Annual Global Healthcare Conference on March 11 at 8:00 a.m. ET - 2025 Leerink Partners Global Healthcare Conference on March 12 at 2:20 p.m. ET [3]

Core Insights - Revolution Medicines, Inc. is set to report its financial results for Q4 and the full year 2024 on February 26, 2025, after market close [1] - A webcast will be hosted by the senior management team at 4:30 p.m. ET to discuss the financial results and corporate progress [1] Company Overview - Revolution Medicines is a late-stage clinical oncology company focused on developing targeted therapies for RAS-addicted cancers [3] - The company's R&D pipeline includes RAS(ON) inhibitors such as daraxonrasib (RMC-6236), elironrasib (RMC-6291), and zoldonrasib (RMC-9805), which are currently in clinical development [3] - Additional pipeline opportunities include RAS(ON) mutant-selective inhibitors like RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C) [3]

Core Viewpoint - Revolution Medicines, Inc. (RVMD) has shown a 1% increase in share price over the past four weeks, closing at $42.19, with analysts suggesting a potential upside of 74.1% based on a mean price target of $73.43 [1] Price Targets - The average of 14 short-term price targets ranges from a low of $62 to a high of $87, with a standard deviation of $7.41, indicating a potential increase of 47% to 106.2% from the current price level [2] - A low standard deviation suggests a strong agreement among analysts regarding the price targets, which can be a good starting point for further research [7] Analyst Sentiment - There is a growing optimism among analysts regarding RVMD's earnings prospects, as indicated by a positive trend in earnings estimate revisions, which historically correlates with stock price movements [9] - The Zacks Consensus Estimate for the current year has increased by 1% over the past month, with no negative revisions, indicating a favorable outlook [10] Zacks Rank - RVMD holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, suggesting a strong potential upside in the near term [11] Caution on Price Targets - While price targets can provide insights, relying solely on them for investment decisions may lead to disappointing returns, and they should be approached with skepticism [8][12]

Core Insights - Revolution Medicines, Inc. is a clinical-stage oncology company focused on developing targeted therapies for RAS-addicted cancers [3] - The company will participate in the Guggenheim Securities SMID Cap Biotech Conference on February 5, 2025, with CEO Mark A. Goldsmith as a speaker [1] Company Overview - Revolution Medicines is developing RAS(ON) inhibitors aimed at suppressing various oncogenic variants of RAS proteins [3] - The R&D pipeline includes daraxonrasib (RMC-6236), elironrasib (RMC-6291), and zoldonrasib (RMC-9805), which are currently in clinical development [3] - Additional pipeline opportunities focus on RAS(ON) mutant-selective inhibitors such as RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C) [3]

Revolution Medicines, Inc. (RVMD) has been on a downward spiral lately with significant selling pressure. After declining 7% over the past four weeks, the stock looks well positioned for a trend reversal as it is now in oversold territory and there is strong agreement among Wall Street analysts that the company will report better earnings than they predicted earlier.Guide to Identifying Oversold StocksWe use Relative Strength Index (RSI), one of the most commonly used technical indicators, for spotting whet ...

REDWOOD CITY, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing novel targeted therapies for patients with RAS-addicted cancers, today announced that Mark A. Goldsmith, M.D., Ph.D., the company’s chief executive officer and chairman, will deliver a corporate presentation as part of the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 10:30 a.m. PT. To access the live webcast of the presentation, pleas ...

REDWOOD CITY, Calif., Dec. 05, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced the closing of its underwritten public offering of 16,576,088 shares of its common stock at a public offering price of $46.00 per share, before underwriting discounts and commissions, and, in lieu of shares of common stock, to certain investors, pre-funded warrants to purchase 2,173,917 share ...

If you like what you have just read and want to receive at least 4 exclusive stock tips every week focused on Pharma, Biotech and Healthcare, then join me at my marketplace channel, Haggerston BioHealth . Invest alongside the model portfolio or simply access the investment bank-grade financial models and research. I hope to see you there.I last covered Revolution Medicines (NASDAQ: RVMD ) for Seeking Alpha back in April, assigning the biotech drug discovery company's stock a "Hold" rating. Shares have risen ...

REDWOOD CITY, Calif., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced the pricing of 14,130,436 shares of its common stock at a public offering price of $46.00 per share, before underwriting discounts and commissions, and, in lieu of shares of common stock, to certain investors, pre-funded warrants to purchase 2,173,917 shares of common stock at a public offeri ...